Navigation Links
LSUHSC'S OCHOA 1 of 10 chosen by NIH director for Transformative Research Award
Date:10/1/2013

New Orleans, LA Dr. Augusto Ochoa, Director of the Stanley S. Scott Cancer Center and Al Copeland/Cancer Crusaders Chair in Neuroendocrine Cancer at LSU Health Sciences Center New Orleans, has been selected as one of ten recipients nationally of the 2013 National Institutes of Health Transformative Research Award. Awarded by NIH Director Dr. Francis Collins, the award comes with a $2.5 million grant over five years to LSUHSC to support the development of new treatments for severe viral diseases, including herpes infections, pandemic influenza and cancers caused viruses, by manipulating how the immune system responds to severe viral and inflammatory infections.

According to the NIH, the NIH Director's Transformative Research Award initiative was created specifically to support exceptionally innovative, groundbreaking, high risk, original, and/or unconventional research projects that have the potential to create or overturn fundamental scientific paradigms. Funded by the NIH Common Fund, projects must clearly demonstrate potential to produce a major impact in a broad area of biomedical or behavioral research. The other recipients are from such places as Harvard, Stanford, and MIT. Dr. Ochoa is the only recipient in Louisiana.

Severe viral diseases, such as infections of the eye and brain caused by herpes viruses, influenza, and certain cancers, are caused by a combination of direct initial damage to the cells by the virus and damage from severe and chronic inflammation resulting from the body's fight against the infection. These diseases are difficult to treat and can cause long-lasting complications, disabilities, and sometimes even death.

Preliminary LSUHSC research on Herpes keratitis, a severe eye infection caused by herpes simplex virus 1 (HSV1) and the most frequent cause of blindness by a infectious agent in developed countries, shows great promise. The LSUHSC research team discovered that a substance produced by the immune system not only kills the virus, but also controls the damaging inflammation that accompanies this disease.

"It is important to find a treatment that can both kill the virus and control inflammation while allowing for the development of protective and long-lasting immunity," notes Dr. Augusto Ochoa, Director of the Stanley S. Scott Cancer Center and Al Copeland/Cancer Crusaders Chair in Neuroendocrine Cancer at LSU Health Sciences Center New Orleans. "Our work suggests that simple and achievable metabolic changes can provide both of these effects and promote the healing of the tissues by altering the way the body responds to viral infections."

The grant will fund a research team including LSUHSC's Dr. Ochoa and Dr. Paulo Rodriguez, leaders in the field of immunology, chronic inflammation and immunotherapy, and Dr. James Hill and Dr. Timothy Foster, experts in ophthalmology and virology, as well as scientists with expertise in cancer immunotherapies and pulmonary infections from the Medical College of Georgia and the University of Tennessee.

Additionally, this award will create two new postdoctoral positions at LSUHSC and will support the training and mentorship of junior scientists, postdoctoral fellows, and graduate students.


'/>"/>

Contact: Leslie Capo
lcapo@lsuhsc.edu
504-568-4806
Louisiana State University Health Sciences Center
Source:Eurekalert

Related biology news :

1. Practicing Sustainability chosen for a silver Nautilus Book Award
2. LSUHSCs Weiss chosen to help set national eye policy, research
3. GW Research chosen as paper of the week for blood coagulation discovery
4. University of Utah researchers receive NIH Directors New Innovator Award
5. Mayo Clinic hosts NIH genomics director at Individualizing Medicine Conference
6. DARPA director: Revolutionary weapons require strong S&T partnerships
7. Stanford bioengineer Christina Smolke wins NIH Directors Pioneer Award
8. George Washington University Computational Biology Director solves 200-year-old oceanic mystery
9. BiOptix announces expansion of Board of Directors
10. Biomedical Advanced Research and Development Authority (BARDA) Exercises Option with Pfenex Inc. To Extend Contract and Increase Funding for the Development of a Recombinant Protective Antigen (rPA) Based Anthrax Vaccine
11. $1.5 million NCI Grant to aid Huntsman Cancer Institute researcher study melanoma, sun damage link
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/23/2017)... The report "Gesture Recognition and Touchless Sensing Market by Technology (Touch-based and ... 2022", published by MarketsandMarkets, the market is expected to be worth USD 18.98 ... Continue Reading ... ...      ...
(Date:3/20/2017)... 20, 2017 At this year,s CeBIT Chancellor Dr. ... manufacturer DERMALOG. The Chancellor came to the DERMALOG stand together with the ... year,s CeBIT partner country. At the largest German biometrics company the two ... face and iris recognition as well as DERMALOG´s multi-biometrics system.   ... ...
(Date:3/9/2017)... MOUNTAIN VIEW, Calif. , March 9, 2017 ... and 23andMe , the leading personal genetics company, ... Zipongo can now provide customers with personalized nutrition plans ... and biometrics, but also genetic markers impacting how their ... Zipongo,s personalized food decision support platform uses biometrics such ...
Breaking Biology News(10 mins):
(Date:3/23/2017)... , March 23, 2017  SeraCare ... to global in vitro diagnostics manufacturers and ... the industry,s first multiplexed Inherited Cancer ... testing by next-generation sequencing (NGS). The Seraseq™ ... developed with input from industry experts to ...
(Date:3/23/2017)... NEW YORK , March 23, 2017 ... ... causes of death, putting significant strain on health care systems, ... of cancer diagnoses rises, so too does the development of ... with minimum side effects. Among the many types of cancer ...
(Date:3/22/2017)... , March 22, 2017 Regeneron Pharmaceuticals, Inc. (NASDAQ: ... Genetics Center (RGC), U.K. Biobank and GSK to generate genetic ... Biobank resource. The initiative will enable researchers to gain valuable ... for a wide range of serious and life threatening diseases. ... Genetic ...
(Date:3/22/2017)... 2017 Oramed Pharmaceuticals Inc. (NASDAQ: ... ), a clinical-stage pharmaceutical company focused ... announced today that Dr. Miriam Kidron , ... titled, "Oral Insulin for Diabetes Treatment: Bypassing the ... and Peptide Therapeutics (OPT) Boston Conference in ...
Breaking Biology Technology: